The Purpose of This Study is to Evaluate Efficacy and Safety of NT-101 Eye Drops in Patients With Wet Age-Related Macular Degeneration (AMD)
Public ClinicalTrials.gov record NCT07811726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase 2 trial is a randomized, double-blind, placebo-controlled, multicenter study in patients with wet AMD to assess the efficacy and safety of NT-101 topical ophthalmic solution (0.20 mM) administered into the study eye twice daily (BID) for 12 weeks.
Study identification
- NCT ID
- NCT07811726
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 10, 2026
- Primary completion
- Feb 27, 2028
- Completion
- Mar 30, 2028
- Last update posted
- Sep 9, 2026
2026 – 2028
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Advanced Retina Institute | Bonita Springs | Florida | 34134 | Recruiting |
| Tulsa Retina Consultants | Tulsa | Oklahoma | 74114 | Recruiting |
| Erie Retina Research | Erie | Pennsylvania | 16505 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Wet Age Related Macular Degeneration trials
Other public records listing Wet Age Related Macular Degeneration. Sorted by last update posted; newest first. Not a recommendation.
- NCT05407636: Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Active, not recruiting
- NCT06683742: A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 Active, not recruiting
- NCT04704921: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD Active, not recruiting
- NCT04504123: MMP-9 Inhibition for Recalcitrant Wet AMD Recruiting
- NCT04645212: Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07811726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07811726 live on ClinicalTrials.gov.